Department of Epidemiology and Biostatistics, School of Public Health, Medical College of Soochow University, 199 Renai Road, Suzhou, 215123, People's Republic of China.
Suzhou Industrial Park Centers for Disease Control and Prevention (Institute of Health Inspection and Supervision), Suzhou, 215021, Jiangsu, People's Republic of China.
Metabolomics. 2018 Aug 31;14(9):117. doi: 10.1007/s11306-018-1408-y.
Hypertension and dyslipidemia are two main risk factors for cardiovascular diseases (CVD). Moreover, their coexistence predisposes individuals to a considerably increased risk of CVD. However, the regulatory mechanisms involved in hypertension and dyslipidemia as well as their interactions are incompletely understood.
The aims of our study were to identify metabolic biomarkers and pathways for hypertension and dyslipidemia, and compare the metabolic patterns between hypertension and dyslipidemia.
In this study, we performed metabolomic investigations into hypertension and dyslipidemia based on a "healthy" UK population. Metabolomic data from the Husermet project were acquired by gas chromatography-mass spectrometry and ultra-performance liquid chromatography-mass spectrometry. Both univariate and multivariate statistical methods were used to facilitate biomarker selection and pathway analysis.
Serum metabolic signatures between individuals with and without hypertension or dyslipidemia exhibited considerable differences. Using rigorous selection criteria, 26 and 46 metabolites were identified as potential biomarkers of hypertension and dyslipidemia respectively. These metabolites, mainly involved in fatty acid metabolism, glycerophospholipid metabolism, alanine, aspartate and glutamate metabolism, are implicated in insulin resistance, vascular remodeling, macrophage activation and oxidised LDL formation. Remarkably, hypertension and dyslipidemia exhibit both common and distinct metabolic patterns, revealing their independent and synergetic biological implications.
This study identified valuable biomarkers and pathways for hypertension and dyslipidemia, and revealed common and different metabolic patterns between hypertension and dyslipidemia. The information provided in this study could shed new light on the pathologic mechanisms and offer potential intervention targets for hypertension and dyslipidemia as well as their related diseases.
高血压和血脂异常是心血管疾病(CVD)的两个主要危险因素。此外,它们的共存使个体面临相当大的 CVD 风险增加。然而,高血压和血脂异常涉及的调节机制及其相互作用尚不完全清楚。
我们研究的目的是确定高血压和血脂异常的代谢生物标志物和途径,并比较高血压和血脂异常之间的代谢模式。
在这项研究中,我们基于“健康”的英国人群进行了高血压和血脂异常的代谢组学研究。Husermet 项目的代谢组学数据通过气相色谱-质谱和超高效液相色谱-质谱获得。使用单变量和多变量统计方法来促进生物标志物选择和途径分析。
高血压或血脂异常个体的血清代谢特征存在显著差异。使用严格的选择标准,分别确定了 26 和 46 种代谢物作为高血压和血脂异常的潜在生物标志物。这些代谢物主要涉及脂肪酸代谢、甘油磷脂代谢、丙氨酸、天冬氨酸和谷氨酸代谢,与胰岛素抵抗、血管重塑、巨噬细胞激活和氧化 LDL 形成有关。值得注意的是,高血压和血脂异常表现出共同和独特的代谢模式,揭示了它们独立和协同的生物学意义。
本研究确定了高血压和血脂异常的有价值的生物标志物和途径,并揭示了高血压和血脂异常之间共同和不同的代谢模式。本研究提供的信息可能为高血压和血脂异常及其相关疾病的病理机制提供新的见解,并为其提供潜在的干预靶点。